Rapport Therapeutics RAPP
$23.16 −$0.43 (-1.82%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $23.16 0.00%
Open$23.23
Prev close$23.59
Day range$23.00 – $23.83
Volume437.7K
Market cap$1.37B
P/E (TTM)–
Dividend yield–
RAPP Stock News
Headlines matching Rapport Therapeutics or the RAPP ticker, most recent first.
- Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and The Estée Lauder Companies (EL)
- A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $66 to $66
- Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and Micron (MU)
- Analysts Offer Insights on NA Companies: Andersen Group, Inc. Class A (ANDG) and Rapport Therapeutics, Inc. (RAPP)
- Rapport Therapeutics, Inc. (RAPP) Receives a Buy From TD Cowen
- Analysts Conflicted on These NA Names: General Dynamics (GD), Rapport Therapeutics, Inc. (RAPP) and First Solar (FSLR)
- A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $66 to $75
- JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50
- A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $50 to $75
- Analysts Conflicted on These NA Names: Rapport Therapeutics, Inc. (RAPP), Idexx Laboratories (IDXX) and Waystar Holding Corp. (WAY)
- Analysts Offer Insights on NA Companies: Jack Henry & Associates (JKHY) and Rapport Therapeutics, Inc. (RAPP)
- Analysts Are Bullish on Top NA Stocks: Rapport Therapeutics, Inc. (RAPP), Paymentus Holdings (PAY) Positive
- Truist Financial Maintains Rapport Therapeutics(RAPP.US) With Buy Rating
- The Bank of Princeton | 4: Statement of changes in beneficial ownership of securities-Officer Rapp George S.
- H.C. Wainwright Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Cuts Target Price to $63 Negative
No comments yet — be the first to weigh in on RAPP.
Sign in to join the discussion.